{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:50:38Z","timestamp":1777895438356,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400094"],"award-info":[{"award-number":["82400094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270069"],"award-info":[{"award-number":["82270069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370073"],"award-info":[{"award-number":["82370073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ajps.2026.101128","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:52:43Z","timestamp":1777621963000},"page":"101128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Hailong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zherui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honggang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajps.2026.101128_bib0001","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","article-title":"Current and future treatment landscape for idiopathic pulmonary fibrosis","volume":"83","author":"Bonella","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ajps.2026.101128_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajps.2026.101128_bib0003","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jare.2022.10.018","article-title":"Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro","volume":"51","author":"Gan","year":"2023","journal-title":"J Adv Res"},{"key":"10.1016\/j.ajps.2026.101128_bib0004","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","article-title":"Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study","volume":"165","author":"Kim","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.ajps.2026.101128_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/imr.12977","article-title":"COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts","volume":"302","author":"John","year":"2021","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ajps.2026.101128_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12939","article-title":"Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis","volume":"53","author":"Li","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.ajps.2026.101128_bib0007","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1038\/s41467-023-40617-y","article-title":"Autocrine TGF-\u03b2-positive feedback in profibrotic AT2-lineage cells plays a crucial role in non-inflammatory lung fibrogenesis","volume":"14","author":"Enomoto","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ajps.2026.101128_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02307-2021","article-title":"Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts","volume":"60","author":"Guan","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajps.2026.101128_bib0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1165\/rcmb.2023-0232OC","article-title":"The regulation of fatty acid synthase by exosomal miR-143-5p and miR-342-5p in idiopathic pulmonary fibrosis","volume":"70","author":"Hayek","year":"2024","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"10.1016\/j.ajps.2026.101128_bib0010","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.3390\/ijms23116064","article-title":"Connective tissue growth factor in idiopathic pulmonary fibrosis: breaking the bridge","volume":"23","author":"Effendi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajps.2026.101128_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ajps.2026.101128_bib0012","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12079-019-00542-6","article-title":"Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis","volume":"13","author":"Leask","year":"2019","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.ajps.2026.101128_bib0013","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ajps.2026.101128_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/nat.2021.0067","article-title":"Modulation of RNA splicing by oligonucleotides: mechanisms of action and therapeutic implications","volume":"32","author":"Sergeeva","year":"2022","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ajps.2026.101128_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajps.2026.101128_bib0016","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.ajps.2026.101128_bib0017","doi-asserted-by":"crossref","first-page":"eadk8264","DOI":"10.1126\/sciadv.adk8264","article-title":"Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality","volume":"10","author":"Liu","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajps.2026.101128_bib0018","doi-asserted-by":"crossref","first-page":"29012","DOI":"10.1021\/acsami.3c06025","article-title":"Zombie\" macrophages for targeted drug delivery to treat acute pneumonia","volume":"15","author":"Xu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.ajps.2026.101128_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41392-023-01703-1","article-title":"Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Sign Transd Target Ther"},{"key":"10.1016\/j.ajps.2026.101128_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ajps.2026.101128_bib0021","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ymthe.2023.01.005","article-title":"RNA editing: expanding the potential of RNA therapeutics","volume":"31","author":"Booth","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajps.2026.101128_bib0022","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-sirp\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"36","key":"10.1016\/j.ajps.2026.101128_bib0023","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.1002\/anie.201405442","article-title":"CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging","volume":"53","author":"Gallo","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.ajps.2026.101128_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-023-01066-8","article-title":"Platelet-derived microparticles stimulate the invasiveness of colorectal cancer cells via the p38MAPK-MMP-2\/MMP-9 axis","volume":"21","author":"Kassassir","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ajps.2026.101128_bib0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.phrs.2015.04.012","article-title":"Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions","volume":"97","author":"Della Latta","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajps.2026.101128_bib0026","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajps.2026.101128_bib0027","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s10753-023-01825-2","article-title":"Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating the PI3K\/Akt\/mTOR pathway in mice","volume":"46","author":"Pan","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.ajps.2026.101128_bib0028","doi-asserted-by":"crossref","first-page":"eabo0987","DOI":"10.1126\/sciadv.abo0987","article-title":"PKM2 promotes pulmonary fibrosis by stabilizing TGF-\u03b21 receptor I and enhancing TGF-\u03b21 signaling","volume":"8","author":"Gao","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajps.2026.101128_bib0029","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0167-7799(02)00038-0","article-title":"LNA: a versatile tool for therapeutics and genomics","volume":"21","author":"Petersen","year":"2003","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.ajps.2026.101128_bib0030","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.ajps.2026.101128_bib0031","doi-asserted-by":"crossref","first-page":"2100864","DOI":"10.1183\/13993003.00864-2021","article-title":"Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis","volume":"59","author":"Song","year":"2022","journal-title":"Eur Respir J"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087626000140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087626000140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:52:48Z","timestamp":1777621968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087626000140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1818087626000140"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2026.101128","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2026.101128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University.","name":"copyright","label":"Copyright"}],"article-number":"101128"}}